The discussion highlights the complexities of primary prevention, particularly regarding the use of statins in women. Evidence suggests benefits for high-risk women in preventing cardiovascular events, but mortality benefits remain unclear. The importance of study duration and adequate power to detect differences is emphasized, suggesting that long-term data could reveal more significant outcomes.
